中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

文献类型:期刊论文

作者Yang, Yong15,16; Wang, Ying17,18; Liu, Xin15,16; He, Xia19,20; Zhang, Li-Ling21; Wu, Gang21,22; Qu, Bao-Lin; Qian, Li-Ting23; Hou, Xiao-Rong24; Zhang, Fu-Quan24
刊名LEUKEMIA
出版日期2020-09-17
ISSN号0887-6924
DOI10.1038/s41375-020-01042-y
通讯作者Qi, Shu-Nan(medata@163.com) ; Li, Ye-Xiong(yexiong12@163.com)
英文摘要Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall survival (OS) in a large-scale multicenter cohort of patients. 1790 patients were included from the China Lymphoma Collaborative Group (CLCG) database. Subsequent OS was defined from the time of PFS24 or progression within 24 months to death. OS was compared with age- and sex-matched general Chinese population using expected survival and standardized mortality ratio (SMR). Patients who did not achieve PFS24 had a median OS of 5.3 months after progression, with 5-year OS rate of 19.2% and the SMR of 71.4 (95% CI, 62.9-81.1). In contrast, 74% patients achieved PFS24, and the SMR after achieving PFS24 was 1.77 (95% CI, 1.34-2.34). The observed OS rate after PFS24 versus expected OS rate at 5 years was 92.2% versus 94.3%. Similarly, superior outcomes following PFS24 were observed in early-stage patients (5-year OS rate, 92.9%). Patients achieving PFS24 had excellent outcome, whereas patients exhibiting earlier progression had a poor survival. These marked differences suggest that PFS24 may be used for study design and risk stratification in ENKTCL.
WOS关键词EVENT-FREE SURVIVAL ; NASAL-TYPE ; CLINICAL DIFFERENCES ; RADIATION-THERAPY ; HIGH-RISK ; RADIOTHERAPY ; MULTICENTER ; GEMCITABINE ; PATTERNS ; OUTCOMES
资助项目National Natural Science Foundation of China[81670185] ; Chinese Academy of Medical Science (CAMS) ; Innovation Fund for Medical Sciences (CIFMS)[2016-I2M-1-001] ; National Key Projects of Research and Development of China[2016YFC0904600]
WOS研究方向Oncology ; Hematology
语种英语
出版者NATURE PUBLISHING GROUP
WOS记录号WOS:000570503500001
资助机构National Natural Science Foundation of China ; Chinese Academy of Medical Science (CAMS) ; Innovation Fund for Medical Sciences (CIFMS) ; National Key Projects of Research and Development of China
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/104097]  
专题中国科学院合肥物质科学研究院
通讯作者Qi, Shu-Nan; Li, Ye-Xiong
作者单位1.Shanxi Canc Hosp, Taiyuan, Shanxi, Peoples R China
2.Shanxi Med Univ, Affiliated Canc Hosp, Taiyuan, Shanxi, Peoples R China
3.Fujian Prov Canc Hosp, Fuzhou, Fujian, Peoples R China
4.Guizhou Med Univ, Guizhou Canc Hosp, Affiliated Hosp, Guiyang, Guizhou, Peoples R China
5.Hunan Canc Hosp, Changsha, Hunan, Peoples R China
6.Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China
7.Fourth Mil Med Univ, Xijing Hosp, Xian, Peoples R China
8.Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
9.Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
10.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Yang, Yong,Wang, Ying,Liu, Xin,et al. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study[J]. LEUKEMIA,2020.
APA Yang, Yong.,Wang, Ying.,Liu, Xin.,He, Xia.,Zhang, Li-Ling.,...&Li, Ye-Xiong.(2020).Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.LEUKEMIA.
MLA Yang, Yong,et al."Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study".LEUKEMIA (2020).

入库方式: OAI收割

来源:合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。